What Is Olaparib?
Olaparib is a prescription anticancer medicine that belongs to a group of medicines called PARP inhibitors. PARP stands for poly(ADP-ribose) polymerase, a family of proteins involved in the repair of damaged DNA.
Olaparib is used in specific cancer-treatment settings where blocking DNA-repair pathways can make cancer cells less able to survive. Depending on the cancer type and applicable treatment guidelines or regulatory approval, olaparib may be used as maintenance treatment or as treatment for certain cancers with particular genetic or molecular characteristics.
On Olaparib150mg.com, the featured products are:
- Olanib 150 mg — Everest Pharmaceuticals Ltd.
- Olakin 150 mg — Ziska Pharmaceuticals Limited
Both contain olaparib 150 mg as the active pharmaceutical ingredient.
Olaparib is not a general-purpose cancer medicine and is not appropriate for every type of cancer. Its use depends on the specific diagnosis, disease stage, previous treatment, biomarker or genetic findings where relevant, and the treatment plan established by the oncology team.
How Does Olaparib Work?
Cancer cells can develop extensive DNA damage as they grow and divide. To survive, cells rely on several systems that detect and repair DNA damage.
PARP proteins are involved in repairing certain types of DNA damage, particularly single-strand DNA breaks. Olaparib inhibits PARP activity and also interferes with PARP-related DNA repair processes.
This becomes especially important in cancer cells that already have weaknesses in other DNA-repair pathways.
One important example involves BRCA1 and BRCA2. These genes are involved in homologous recombination, a major pathway used to repair certain forms of DNA damage. Cancer cells with harmful BRCA-related defects may have reduced ability to repair DNA through this pathway.
When PARP activity is also inhibited, the cancer cell may become unable to adequately repair accumulating DNA damage. This can result in cancer-cell death.
This general principle is sometimes described as synthetic lethality: blocking one repair pathway can be particularly damaging to cells that already have a defect in another important repair pathway.
The effect is not simply that olaparib “kills cancer cells” directly. Rather, it interferes with DNA-repair mechanisms that some cancer cells depend on for survival.
What Does PARP Mean?
PARP refers to poly(ADP-ribose) polymerase.
PARP proteins have important roles in cellular responses to DNA damage. When DNA is damaged, PARP proteins can participate in recognizing the damage and coordinating repair processes.
Olaparib binds to PARP proteins and inhibits their enzymatic activity. It can also cause PARP proteins to remain associated with DNA, a phenomenon known as PARP trapping.
Both PARP inhibition and PARP trapping contribute to the medicine’s anticancer activity.
The degree to which a particular cancer responds to olaparib can depend on the biological characteristics of the tumor and its ability to repair DNA.
Why Are BRCA Mutations Important?
BRCA1 and BRCA2 are genes involved in DNA repair. Harmful mutations in these genes can impair the homologous recombination repair pathway.
Some ovarian, breast, prostate, and other cancers contain BRCA mutations. Depending on the cancer type and treatment setting, identification of a relevant BRCA mutation can help determine whether olaparib is an appropriate treatment option.
BRCA testing may involve germline testing, which looks for inherited genetic changes, or somatic testing, which looks for changes present in the tumor.
These are not interchangeable concepts.
A germline BRCA mutation is present in cells throughout the body and may have implications for family members. A somatic BRCA mutation is acquired by tumor cells and may not be inherited.
Patients should discuss the meaning of genetic or biomarker test results with their oncologist or an appropriately qualified genetics professional.
Olaparib and Homologous Recombination Deficiency
Another important biological concept associated with olaparib treatment is homologous recombination deficiency (HRD).
Homologous recombination is one of the major pathways used by cells to repair DNA double-strand breaks. When this repair system is impaired, cancer cells may become more dependent on alternative DNA-repair mechanisms.
PARP inhibition can exploit this vulnerability in selected cancers.
HRD testing may use a combination of genetic and genomic information. The precise definition of HRD and the testing requirements can vary depending on the cancer type, treatment regimen, and applicable regulatory indication.
Therefore, a patient should not assume that having cancer automatically means that olaparib will be effective. Eligibility depends on the clinical and molecular characteristics relevant to the particular treatment indication.
What Is Olaparib 150 mg?
Olaparib is available in tablet formulations in different strengths.
The 150 mg tablet contains 150 mg of olaparib as the active ingredient. The 150 mg strength may be used as part of an individualized dosing regimen.
Importantly, seeing “150 mg” on a tablet does not necessarily mean that the standard total daily dose is 150 mg. For some approved indications, the usual adult dose of olaparib tablets is 300 mg twice daily, which can be administered as two 150 mg tablets per dose.
Dose adjustments may be necessary in certain circumstances, including impaired kidney function or adverse reactions. Therefore, patients should take the exact number of tablets prescribed for them rather than determining the dose from the tablet strength alone.
How Olaparib Is Taken
Olaparib tablets are taken by mouth.
For applicable approved indications, the standard tablet dosing regimen is commonly 300 mg twice daily, approximately 12 hours apart, although the prescribed dose can differ according to the patient’s circumstances.
Olaparib tablets may generally be taken with or without food.
Patients should swallow the tablets whole with water. They should not crush, chew, dissolve, or break tablets unless specifically instructed by a healthcare professional.
The exact treatment schedule depends on the indication and the prescribing information applicable to the patient.
What Happens If a Dose Is Missed?
If a patient misses an olaparib dose, they should follow the instructions provided by their prescribing healthcare professional or the product information.
The FDA prescribing information advises patients not to take an additional dose to make up for a missed dose. The next scheduled dose should generally be taken at the regular time.
Patients should not double their dose unless specifically instructed by their healthcare professional.
Why Regular Dosing Matters
Olaparib treatment is intended to maintain sustained inhibition of PARP activity. Taking doses consistently helps maintain the prescribed treatment exposure.
Patients should try to take their medicine at approximately the same times each day.
If nausea, fatigue, difficulty swallowing, forgetfulness, or another problem makes regular dosing difficult, the patient should inform the healthcare team rather than independently changing the schedule.
The oncology team may be able to recommend strategies to improve treatment tolerance or adherence.
How Long Is Olaparib Treatment Continued?
The duration of olaparib treatment varies considerably.
In some treatment settings, olaparib is used as maintenance therapy, meaning it is continued after a patient has responded to previous cancer treatment in order to delay disease progression.
In other settings, it may be administered as active treatment for advanced or metastatic disease.
Treatment duration may depend on:
- Cancer type
- Stage and extent of disease
- Genetic or biomarker findings
- Previous cancer treatments
- Response to treatment
- Side effects
- Blood-count results
- Kidney function
- Other medical conditions
- The specific approved treatment regimen
Patients should not stop olaparib simply because they feel well. Similarly, treatment should not be continued indefinitely without appropriate medical review.
Important Monitoring During Treatment
Olaparib can affect blood-cell production, so healthcare professionals may perform complete blood counts (CBCs) before and during treatment.
Monitoring may help identify anemia, neutropenia, thrombocytopenia, or other changes that could require medical attention.
Kidney function can also be important because renal impairment may affect olaparib exposure and may require dose adjustment.
Depending on the patient’s cancer and overall health, the oncology team may perform additional laboratory tests, examinations, imaging studies, or other assessments to determine whether treatment is working and whether it remains appropriate.
Olaparib Is a Targeted Cancer Treatment
Olaparib is often described as a targeted therapy because it acts on a specific biological process rather than functioning like a traditional nonspecific cytotoxic chemotherapy drug.
However, targeted treatment does not mean that side effects are impossible.
Because DNA-repair processes are important to normal cells as well as cancer cells, olaparib can affect healthy tissues. Common adverse effects include nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, and other laboratory or clinical abnormalities.
Some potentially serious complications can occur and require medical attention.
Important Safety Considerations
Olaparib can cause significant adverse reactions. Important warnings include the possibility of:
- Myelodysplastic syndrome or acute myeloid leukemia
- Bone-marrow suppression and significant blood-count abnormalities
- Pneumonitis
- Embryo-fetal toxicity during pregnancy
Patients should tell their healthcare professional about pregnancy, plans to become pregnant, breastfeeding, existing medical conditions, and all medicines or supplements they use.
Olaparib can also interact with other medicines, including medicines that affect CYP3A enzymes. The oncology team should review the patient’s complete medication list before and during treatment.
Who May Benefit From Olaparib?
Olaparib may be appropriate for selected patients with certain cancers and molecular characteristics.
Depending on the applicable regulatory approval, treatment settings can include specific forms of:
- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Breast cancer
- Pancreatic cancer
- Metastatic castration-resistant prostate cancer
- Certain other cancers or treatment combinations in jurisdictions where approved
The precise eligibility criteria differ by cancer type and country.
For example, some indications require a BRCA1/2 mutation, while other approved settings may involve broader homologous-recombination or genomic-instability criteria.
Therefore, the question “Can I take olaparib?” cannot be answered from the medicine name alone. A qualified cancer specialist must consider the patient’s complete clinical and molecular information.
Olanib 150 mg and Olakin 150 mg
The two products featured on this website provide branded versions of olaparib 150 mg:
| Product | Active Ingredient | Strength | Company |
|---|---|---|---|
| Olanib 150 mg | Olaparib | 150 mg | Everest Pharmaceuticals Ltd. |
| Olakin 150 mg | Olaparib | 150 mg | Ziska Pharmaceuticals Limited |
The products should be used according to their respective prescribing information and the instructions given by the treating healthcare professional.
Key Takeaway
Olaparib is a specialized PARP inhibitor designed to exploit weaknesses in DNA-repair mechanisms in selected cancer cells. Its effectiveness is closely connected to the biological characteristics of the cancer and, in appropriate treatment settings, genetic or molecular biomarkers such as BRCA1/2 mutations or homologous recombination deficiency.
Olanib 150 mg and Olakin 150 mg both contain olaparib 150 mg, but the products are associated with different pharmaceutical companies.
Because olaparib can cause serious adverse effects and interact with other medicines, it should only be used under appropriate medical supervision. Patients should follow the prescribed dose and schedule, attend recommended laboratory and clinical monitoring, and promptly report concerning symptoms to their healthcare team.